Zacks.com on MSN4d
GSK Posts New Data From Phase III Study on RSV Vaccine ArexvyNew data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
MyChesCo on MSN11h
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV SeasonsGSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...
GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...
GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...
GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...
The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV) vaccine, Arexvy, for protection against lower respiratory tract disease (LRTD) caused by RSV in adults ...
GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk Safety and reactogenicity data are consistent ...
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback